Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C.
about
Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus InfectionCofactor dependence and isotype distribution of anticardiolipin antibodies in viral infectionsAntiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipidsAnticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndromeTreatment of hepatitis C related thrombocytopenia with interferon alpha.Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome.Prevalence of antiphospholipid and antiplatelet antibodies in human immunodeficiency virus (HIV)-infected Chilean patients.Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura.Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia.Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection: A Case ReportRetinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature.Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease.Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infectionAPhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome.Hepatitis C virus and autoimmunity.Autoantibodies in nonautoimmune individuals during infections.Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis.Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients.Ig M class anticardiolipin antibody and anti-Ro/SS-A positivity in urticarial vasculitis associated with hepatitis C virus infection.Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients.
P2860
Q26775733-6CFFCDA6-E23F-491E-B628-CBC70BD06783Q28362586-13B8C8CF-83CE-489E-A949-C44B5965E36DQ28364192-53A1A60D-630C-4272-A100-0E0EC91D479DQ33331690-11C7F19D-A70A-4CE8-A1D1-FE03D5C350C5Q33340288-83CA3413-DEEC-4C8D-AEDB-DC71F8F69B58Q33346556-2E495627-FC85-4403-8D5D-9A375E4E6E38Q33357573-F5DA15FC-611B-4FA2-A759-EE1F05E94595Q33366747-8EAA2B5D-3C87-4A4E-9E31-7D260304C956Q33368703-3FEA1731-7F2B-4DAE-B40D-EBAC00E97293Q33425472-A8CB0F62-2B31-46BF-94FC-F22B39B09896Q34103850-A5E1B393-4EE1-445A-AF6C-427BD8A12D62Q35552173-77A01B2E-F2CC-4B55-A567-832E6F2FF9BDQ35731058-895F2995-21C9-4615-95AB-EE56FC9A6317Q35926536-F441B5D7-54E0-4121-83A1-E4A722E2A492Q38497354-43331D0E-DB29-42C5-9118-054EF70D67C3Q40438328-6A4DFAFA-9542-4973-8559-67576344B8E8Q41930841-CF3BE50A-5A16-4B61-BF73-70D098A18B56Q45397876-46C44FFB-55FC-4068-B95D-64CBB6C67A86Q45729789-A0C4030E-3CAF-4754-B399-26643F2CD87FQ46934192-DCEF99CE-0CD9-40F4-99E7-6FC9DD028CE4Q51381212-2B6A7457-67DF-46FA-9FDC-4274696A9285
P2860
Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Prevalence and significance of ...... bodies in chronic hepatitis C.
@ast
Prevalence and significance of ...... bodies in chronic hepatitis C.
@en
type
label
Prevalence and significance of ...... bodies in chronic hepatitis C.
@ast
Prevalence and significance of ...... bodies in chronic hepatitis C.
@en
prefLabel
Prevalence and significance of ...... bodies in chronic hepatitis C.
@ast
Prevalence and significance of ...... bodies in chronic hepatitis C.
@en
P2093
P2860
P1476
Prevalence and significance of ...... bodies in chronic hepatitis C.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2141.1998.00722.X
P407
P577
1998-06-01T00:00:00Z